Identifying Specific mAb Binders to a CAR, Enabling Drug Quantification in Patient Serum Sample

Identifying specific mAb binders to a CAR, enabling drug quantification in patient serum sample. Partner required a diverse panel of anti-idiotypic mAbs against the antigenic determinant of ‘CAR-T X’ to support functional measurements in an upcoming clinical trial.

Covered in this Case Study

A discovery workflow combining broadened antibody diversity and stringent screening to identify ideal mAbs

Successful discovery of a highly diverse panel of over 80 specific CAR-T X on cell binders

Validated antibodies with confirmed on-cell binding activity and lack of matrix effects, screened in the presence of human serum

Share your details to Get the Case Study

Genes

Oligo Pools

NGS Target Enrichment Solutions

Variant Libraries

Synthetic Controls

Antibody Discovery

Identifying Specific mAb Binders to a CAR, Enabling Drug Quantification in Patient Serum Sample

Related Resources

Ultrafast, Single B Cell-based Anti-idiotypic mAb Discovery Against a mAb Therapeutic

Hybridoma-based Anti-idiotypic mAb Discovery against a Bispecific Therapeutics for PK/ADA Assays Development

Twist cfDNA Pan-Cancer Reference standard VAF 0% (WT), 3ug (SDS-001098)